Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

JAZZ PHARMACEUTICALS Earnings Preview: Recent $JAZZ Insider Trading, Hedge Fund Activity, and More

None

JAZZ PHARMACEUTICALS ($JAZZ) is expected to release its quarterly earnings data on Tuesday, February 25th after market close, per Finnhub. Analysts are expecting revenue of $1,081,052,548 and earnings of $5.93 per share.

You can see Quiver Quantitative's $JAZZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

JAZZ PHARMACEUTICALS Insider Trading Activity

JAZZ PHARMACEUTICALS insiders have traded $JAZZ stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:

  • BRUCE C COZADD (Chairman & CEO) has made 0 purchases and 4 sales selling 6,000 shares for an estimated $721,790.
  • NEENA M PATIL (EVP & Chief Legal Officer) sold 3,700 shares for an estimated $456,617
  • MARY ELIZABETH HENDERSON (SVP, Technical Operations) sold 1,410 shares for an estimated $152,703
  • PATRICIA CARR (SVP, Chief Accounting Officer) sold 53 shares for an estimated $6,491

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

JAZZ PHARMACEUTICALS Hedge Fund Activity

We have seen 235 institutional investors add shares of JAZZ PHARMACEUTICALS stock to their portfolio, and 263 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles